^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD19-targeted CAR-T immunotherapy

    Related drugs:
    1d
    Lythesia: A Non-Interventional Study PASS to Characterize Secondary Malignancies of Tcell Origin Following Tisagenlecleucel Therapy (clinicaltrials.gov)
    P=N/A, N=30, Not yet recruiting, Novartis Pharmaceuticals
    New trial
    |
    Kymriah (tisagenlecleucel-T)
    1d
    Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas (clinicaltrials.gov)
    P2, N=28, Active, not recruiting, Patrick C. Johnson, MD | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    cyclophosphamide • Calquence (acalabrutinib) • Breyanzi (lisocabtagene maraleucel) • fludarabine IV
    3d
    A single-arm, single-center, open-label clinical study on the efficacy and safety of CAR-T combined with ASCT in the treatment of relapsed/refractory large B-cell lymphoma with high-risk factors (ChiCTR2600116310)
    P4, N=20, Not yet recruiting, Zhejiang Cancer Hospital; Zhejiang Cancer Hospital
    New P4 trial
    |
    TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    TP53 mutation
    |
    Yescarta (axicabtagene ciloleucel)
    3d
    A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov)
    P1, N=3, Completed, Peking University | Recruiting --> Completed | N=18 --> 3
    Trial completion • Enrollment change
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD20 positive
    |
    prizloncabtagene autoleucel (JNJ-4496)
    4d
    Precision immunotherapy with CAR-T cells in pediatric B-cell acute lymphoblastic leukemia: advances and unanswered challenges. (PubMed, Front Oncol)
    CD19-targeted CAR T cells, such as tisagenlecleucel, have demonstrated high rates of complete remission and long-lasting responses in clinical trials...Despite these innovations, further research is needed to refine manufacturing processes, reduce costs, and improve long-term outcomes. This review emphasizes the transformative potential of CAR-T therapy for pediatric B-ALL and discusses critical challenges and future directions in the field.
    Review • Journal
    |
    CD22 (CD22 Molecule)
    |
    Kymriah (tisagenlecleucel-T)
    4d
    A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Suzhou Immunofoco Biotechnology Co., Ltd
    New P1/2 trial
    |
    CD19 positive • CD20 negative
    5d
    IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy (clinicaltrials.gov)
    P1, N=3, Terminated, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | N=36 --> 3 | Trial completion date: Oct 2026 --> Oct 2025 | Recruiting --> Terminated | Trial primary completion date: May 2025 --> Oct 2025; The collaborating party has adjusted its R&D strategy and terminated the study.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV
    6d
    Apheresis CD8+CCR7+CD45RA- T-Cells as a Novel Biomarker Associated with CAR T-Cell Kinetics and Clinical Outcome. (PubMed, Int J Mol Sci)
    In apheresis, a cut-off value of >4.3% of CD8+ TCM predicted strong CAR-T expansion (AUC: 0.80; p = 0.023) and superior progression-free survival (p = 0.04) compared with patients who had CD8+ TCM below the cut-off. Our data suggest that high frequencies of CD8+ TCM cells in apheresis samples may represent a promising pre-treatment biomarker associated with strong CAR-T expansion and superior clinical outcome in r/r LBCL patients following axi-cel.
    Clinical data • Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD38 (CD38 Molecule) • CCR7 (Chemokine (C-C motif) receptor 7)
    |
    Yescarta (axicabtagene ciloleucel)
    6d
    MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P=N/A, N=12, Not yet recruiting, King Hussein Cancer Center
    New trial
    |
    CD19 (CD19 Molecule)
    |
    zorpocabtagene autoleucel (MB-CART 19.1)
    7d
    Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P1, N=30, Recruiting, Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
    New P1 trial
    |
    CD19 positive
    |
    cyclophosphamide
    7d
    Clinical Study of Universal CD19 CAR-γδT Cell Injection in the Treatment of Adult Relapsed/Refractory B-cell Lymphoma (clinicaltrials.gov)
    P1, N=6, Not yet recruiting, The Second Affiliated Hospital of Fujian Medical University
    New P1 trial
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD19 positive
    |
    cyclophosphamide • fludarabine IV
    9d
    CAR-T cells with the CD38-CD73-Tim-3-HLA-DR+ phenotype predict the efficacy of tisagenlecleucel as a treatment for B cell precursor ALL. (PubMed, Cell Rep Med)
    By contrast, CARpos T cells obtained from infusion products in long-term responders are enriched in the CD38-CD73-Tim-3-HLA-DR+ phenotype, characterized by a decreased ability to produce adenosine, memory-like transcriptomic characteristics, and leveraging of mitochondrial metabolism and oxidative phosphorylation. Our study reveals that the CD38-CD73-Tim-3-HLA-DR+ phenotype contributes to long-term remission in patients with BCP-ALL who receive tisagenlecleucel.
    Journal
    |
    CD73 (5'-Nucleotidase Ecto) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CXCR3 (C-X-C Motif Chemokine Receptor 3)
    |
    Kymriah (tisagenlecleucel-T)